JP2006232711A - Oil and fat having blood neutral fat-reducing activity, hepatic neutral fat synthesis-inhibiting activity and platelet aggregation-inhibiting activity - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide oils and fats having an improving activity of serum lipid and/or a hepatic neutral fat-reducing activity and/or a platelet aggregation-inhibiting activity, obtained by utilizing general purpose oil seeds, having less adverse effects, simple and usable daily. <P>SOLUTION: The oils and fats having an extremely potent blood neutral fat-reducing activity and/or hepatic neutral fat synthesis-inhibiting activity and/or platelet aggregation-inhibiting activity are provided with that the ratio of 5,11,14-eicosatrienoic acid occupying the total fatty acids constituting triglycerides is 8-50 mass%. <P>COPYRIGHT: (C)2006,JPO&NCIPI

Description

  The present invention relates to fats and oils having blood neutral fat lowering action and / or liver neutral fat synthesis inhibiting action and / or platelet aggregation inhibiting action.

  Hyperlipidemia, which is a state in which the serum lipid content is increased, promotes arteriosclerosis and is considered to be a cause of coronary artery disease and stroke. In particular, an increase in neutral fat is associated with the onset of fatty liver and pancreatitis, and is considered a risk factor for ischemic heart disease. In particular, fatty liver, which causes cirrhosis and liver cancer, is also caused by excessive alcohol consumption and overnutrition. Thrombosis caused by platelet aggregation is also known to cause ischemic heart disease and stroke, but since these are affected by daily diet, improvement of eating habits is required.

  As a technique for solving these problems, administration of antihyperlipidemic agents such as clofibrate and cholestyramine nicotinate can be mentioned. However, these drugs cause many side effects such as liver dysfunction as side effects, and are not particularly suitable for the treatment of fatty liver.

  From such a viewpoint, there is a need for a method that can be used inexpensively and routinely, and can safely prevent and treat hyperlipidemia, fatty liver, and thrombosis without side effects.

  Thus, it has been clarified that highly unsaturated fatty acids such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) reduce serum neutral fat level and cholesterol level and suppress platelet aggregation (non-patented). From literature 1), for the prevention and treatment of hyperlipidemia and thrombosis, intentionally ingesting fish containing a large amount of such fatty acids, and health foods made from fish oil or fish oil concentrate are commercially available. It came to be. However, such highly unsaturated fatty acid fats and oils are easily oxidized and are not suitable for use as edible fats and oils such as tempura oil and salad oil used for daily cooking.

  On the other hand, nagi seeds, scented hiyaba seeds, yew seeds, konotegasiwa seeds, Korean pine seeds, silkworm show seeds and the like are 5,9,12-octa of highly unsaturated fatty acids whose double bond arrangement is a non-methylene mediated type. Decatrienoic acid (all cis-5,9,12-octadecatrienoic acid, pinolenic acid) and / or 5,11,14-eicosatrienoic acid (all cis-5,11,14-eicosatrienoic acid, cyanidic acid) and / or Alternatively, it is known that 5,11,14,17-eicosatetraenoic acid (all cis-5,11,14,17-eicosatetraenoic acid acid, juniperonic acid) exists. Among these, it has been reported that seed oil of Konotegasiwa, Korean pine, and silkworm show has an action of improving serum lipids and an action of reducing liver neutral fat (Non-Patent Documents 2 to 7). As the active ingredient, non-methylene mediated highly unsaturated fatty acids are considered, but since an active ingredient contains a plurality of non-methylene mediated highly unsaturated fatty acids having different structures, no active ingredient is specified.

Fishery lipids-Their properties and physiological effects-1993, published by Hoshiseisha Koseikaku, pp. 80-87 Lipids, 1992, Vol. 27, No. 7, pp. 500-504 British Journal of Nutrition, 1994, Vol. 72, pp. 775-783 Journal of Nutrition, 1999, Vol. 129, pp. 1972-1978 Lipids, 1999, Vol. 34, No. 1, pp. 39-44 British Journal of Nutrition, 2000, Vol. 84, pp.353-360 Lipids, 2001, Vol. 36, No. 6, pp. 567-574

  An object of the present invention is to provide a serum lipid improving action and / or a liver triglyceride lowering action and / or a platelet aggregation inhibitory action using general-purpose oil seeds with few side effects and which can be used easily and daily. It is in providing the fats and oils to have.

  As a result of intensive studies on the correlation between various seed oils and serum lipid and liver lipid lowering effects, the present inventors have found that 5,11,14- The oil and fat extracted from kaya seeds containing only eicosatrienoic acid has been found to have an extremely strong blood neutral fat lowering action and / or liver neutral fat synthesis inhibiting action and / or platelet aggregation inhibiting action. It came to be completed.

  According to the present invention, kaya seeds containing 5,11,14-eicosatrienoic acid having a very strong blood neutral fat lowering action and / or liver neutral fat synthesis inhibiting action and / or platelet aggregation inhibiting action, etc. Oils and fats extracted from are provided. The fats and oils can be used alone, or can be blended with known raw materials to form foods, drinks, health foods, animal feeds or pharmaceutical preparations, and can be used simply without concern about side effects.

  Kaya oil or other oil seeds containing 5,11,14-eicosatrienoic acid have been widely used as edible oils, and have no safety problems. Moreover, the fats and oils which concern on this invention have the flavor equivalent to or more than the normal edible fats and oils generally marketed, and can replace the conventional edible fats and oils. Like normal oils and fats, it can be used for all kinds of cooking such as fried foods and fried foods, as well as dressings, mayonnaise, margarines, creams, confectionery, breads, cakes, chocolates, ice creams that contain oils and fats. Can also be used. It can also be used for business use, for lunch, for health food, for treatment, and for hospital use without stopping for general household use. That is, according to the present invention, an effect of improving serum neutral fat and / or fatty liver and / or thrombosis can be obtained by daily intake as an edible oil.

  The fats and oils according to the present invention can be ingested in the form of capsules such as soft capsules and microcapsules together with other edible animal and vegetable oils and fats, vitamin E, β-carotene and the like. Thus, the oil and fat according to the present invention can be expected to be used for the prevention and treatment of hyperlipidemia, fatty liver and thrombosis.

  In order to describe the present invention more specifically, test examples are shown below. Of course, the present invention is not limited thereto.

  Explaining the test examples, feeds containing 10 wt% of kaya oil, soybean oil and corn oil (the fatty acid composition of each test oil is shown in Table 1) in 4 weeks old SD male rats (Table 2). For 4 weeks. Four weeks later, 8 animals were collected from each test group by dissection, and the serum lipid concentration was measured by a conventional method. Moreover, while measuring the weight of the liver tissue of the rat of each test group, the amount of cholesterol, triglyceride, and phospholipid was measured. In addition, the fatty acid composition of blood phospholipid, which is an important factor of platelet aggregation, was analyzed. Statistical processing was performed with the soybean oil added group and the corn oil added group as controls, and a risk rate of 5% or less was regarded as a significant difference. Table 3 shows serum lipid concentration, and Table 4 shows liver tissue weight and liver lipid concentration. There was no significant difference in feed intake, body weight gain, or liver weight in each test group. The test group to which kaya oil was added showed significantly lower serum neutral fat and liver neutral fat concentrations than the test group to which soybean oil and corn oil were added. Moreover, as a result of analyzing the fatty acid composition of blood phospholipid, as shown in Table 5, the ratio of 18: 2 and 20: 4 fatty acids decreased, and cyanidic acid (20: 3) increased. Since 20: 4 and 18: 2 are raw materials for thromboxane A2 having a strong platelet aggregation ability, it is known that platelet aggregation tends to occur when the concentration of these fatty acids in blood phospholipids is high. In addition, although the structure of siadonic acid is similar to that of 20: 4, it is not a raw material for thromboxane A2, and therefore, it is considered that the synthesis of thromboxane A2 is competitively suppressed. Therefore, the intake of kaya oil changes the fatty acid composition of blood phospholipids and decreases the production of thromboxane A2, which has a strong platelet aggregation action. Therefore, it can be said that kaya oil has a platelet aggregation inhibitory action. From these experimental results, it is clear that the triglyceride (kaya oil) according to the present invention has no side effects on rats, significantly reduces serum neutral fat and liver neutral fat levels, and has an effect of inhibiting platelet aggregation. Became.

Claims (9)

  A blood neutral fat lowering agent comprising 5,11,14-eicosatrienoic acid as an active ingredient.   A liver neutral fat synthesis inhibitor comprising 5,11,14-eicosatrienoic acid as an active ingredient.   A platelet aggregation inhibitor comprising 5,11,14-eicosatrienoic acid as an active ingredient.   An oil having a blood neutral fat lowering action, characterized by comprising an effective amount of 5,11,14-eicosatrienoic acid glyceride.   An oil or fat having an action of inhibiting the synthesis of neutral fat in liver, comprising an effective amount of 5,11,14-eicosatrienoic acid glyceride.   An oil having an action of inhibiting platelet aggregation, comprising an effective amount of 5,11,14-eicosatrienoic acid glyceride.   The fats and oils according to claims 4 to 6, wherein 5,11,14-eicosatrienoic acid glyceride is obtained from kaya seeds, or is obtained by concentrating them or subjected to transesterification.   Edible fats and oils containing the fats and oils of any one of Claims 4-7.   The fats and oils processed product containing the fats and oils of any one of Claims 4-8.